Masimo Corporation
146.41-1.59 (-1.07%)
Oct 28, 4:00:01 PM EDT · NasdaqGS · MASI · USD
Key Stats
Market Cap
7.95BP/E (TTM)
-Basic EPS (TTM)
-5.09Dividend Yield
0%Recent Filings
8-K
Masimo sells audio unit to Harman
Masimo Corporation completed the sale of its consumer audio business, Sound United, to Harman International on September 23, 2025, for $328 million in cash after adjustments from the $350 million base. The company used proceeds to repay its $270 million term loan plus $1.1 million interest, slashing interest expense by $13.5 million annually while booking a $178.4 million loss on disposal. This sharpens focus on core operations, boosting pro forma net income to $27.2 million for 2024. Post-closing adjustments loom.
8-K
Director resigns abruptly
Masimo Corporation's board saw a sudden shift on August 18, 2025, when director William Jellison resigned effective immediately, citing no disagreements with company operations or policies. Chairman Michelle Brennan praised his contributions during a key growth phase, signaling smooth continuity. Yet the board now operates one member short. No successor named yet.
10-Q
Q2 FY2025 results
Masimo's healthcare revenue climbed 7.9% y/y to $370.9M in Q2 FY2025 ended June 28, 2025, fueled by stronger consumables while capital sales dipped; gross margin expanded to 62.9% from 60.3% on efficiencies offsetting $1.9M tariff hits. Operating income rose 53.9% y/y to $64.5M as SG&A edged up 10.0% to $138.9M on legal fees and a $4.5M cybersecurity incident (net of $1.0M insurance), yet R&D fell 23.5% to $29.9M via cost controls. Diluted EPS from continuing ops hit $0.82, up 78.3% y/y, aligning with 54.8M shares. Cash swelled to $149.6M with $99.5M operating cash flow; debt dropped to $613.7M (5.7% rate, $355.2M revolver availability, compliant covenants). The non-healthcare unit, set for $350M cash sale to Harman by year-end (closing May 2025, subject to approvals), posted $6.4M net income vs. $8.8M loss y/y. Patent disputes with Apple loom large.
8-K
Masimo Q2 revenue up 8%
Masimo reported Q2 2025 continuing operations revenue of $371 million, up 8% year-over-year, with non-GAAP EPS surging 46% to $1.33 amid strong healthcare demand. Operating margins expanded 600 basis points to 27.5%, boosted by tariff mitigation that halved the expected impact. Full-year guidance holds at $1,505-$1,535 million revenue, yet tariffs pose escalating quarterly risks.
8-K
Masimo announces leadership changes
Masimo Corporation bolstered its leadership team with key hires to enhance commercial excellence: Tim Benner as Chief Marketing and Strategy Officer starting June 9, 2025; Huimin Wang as President, Japan & Asia Pacific from May 13, 2025; and Lisa Hellmann as Chief Human Resources Officer since April 21, 2025. CFO Micah Young now leads corporate development alongside finance, IT, and investor relations. COO Bilal Muhsin resigns effective July 1, 2025, with no replacement planned. These shifts aim to sharpen strategy amid an active search for a Chief Commercial Officer.
BRKR
Bruker Corporation
38.72+0.08
BSX
Boston Scientific Corporation
100.97-1.46
ENOV
Enovis Corporation
32.86+0.00
HAE
Haemonetics Corporation
50.36-0.85
IRIX
IRIDEX Corporation
1.01-0.05
IRMD
iRadimed Corporation
79.79+2.06
IRME
IR-Med Inc.
0.03+0.00
MDT
Medtronic plc.
93.23-0.90
NMTC
NeuroOne Medical Technologies C
0.82-0.02
RMD
ResMed Inc.
256.57-2.64